Chemical Works of Gedeon Richter Plc (RGEDF)
41.20
+0.76
(+1.87%)
USD |
OTCM |
Oct 26, 16:00
Chemical Works of Gedeon Richter Enterprise Value : 6.696B for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 6.696B |
| October 23, 2026 | 6.558B |
| October 22, 2026 | 6.371B |
| October 21, 2026 | 6.371B |
| October 20, 2026 | 6.445B |
| October 19, 2026 | 6.409B |
| October 16, 2026 | 6.333B |
| October 15, 2026 | 6.226B |
| October 14, 2026 | 6.109B |
| October 13, 2026 | 6.211B |
| October 12, 2026 | 6.178B |
| October 09, 2026 | 5.950B |
| October 08, 2026 | 5.698B |
| October 07, 2026 | 5.744B |
| October 06, 2026 | 6.211B |
| October 05, 2026 | 6.097B |
| October 02, 2026 | 6.177B |
| October 01, 2026 | 6.185B |
| September 30, 2026 | 6.318B |
| September 29, 2026 | 6.242B |
| September 28, 2026 | 6.270B |
| September 25, 2026 | 6.393B |
| September 24, 2026 | 6.247B |
| September 23, 2026 | 6.279B |
| September 22, 2026 | 6.658B |
| Date | Value |
|---|---|
| September 21, 2026 | 6.819B |
| September 18, 2026 | 6.664B |
| September 17, 2026 | 6.748B |
| September 16, 2026 | 6.499B |
| September 15, 2026 | 6.348B |
| September 14, 2026 | 6.501B |
| September 11, 2026 | 6.365B |
| September 10, 2026 | 6.653B |
| September 09, 2026 | 6.594B |
| September 08, 2026 | 6.596B |
| September 04, 2026 | 6.729B |
| September 03, 2026 | 6.516B |
| September 02, 2026 | 6.614B |
| September 01, 2026 | 6.875B |
| August 31, 2026 | 6.880B |
| August 28, 2026 | 7.071B |
| August 27, 2026 | 7.071B |
| August 26, 2026 | 7.108B |
| August 25, 2026 | 7.165B |
| August 24, 2026 | 7.083B |
| August 21, 2026 | 6.808B |
| August 20, 2026 | 6.808B |
| August 19, 2026 | 6.934B |
| August 18, 2026 | 6.791B |
| August 17, 2026 | 6.848B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 559.97B |
| ANI Pharmaceuticals, Inc. | 1.902B |
| Corcept Therapeutics, Inc. | 9.104B |
| Veru, Inc. | 14.57M |
| Avadel Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 122.85M |
| Revenue (Quarterly) | 777.18M |
| Total Expenses (Quarterly) | 653.98M |
| EPS Diluted (Quarterly) | 0.6729 |
| Gross Profit Margin (Quarterly) | 70.03% |
| Profit Margin (Quarterly) | 15.81% |
| Earnings Yield | 8.74% |
| Operating Earnings Yield | 13.31% |
| Normalized Earnings Yield | 8.738 |